Dasiglucagon
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Type 1 Diabetes
Trial Timeline
May 9, 2023 → Dec 3, 2024
NCT ID
NCT05378672About Dasiglucagon
Dasiglucagon is a phase 3 stage product being developed by Novo Nordisk for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05378672. Target conditions include Hypoglycemia, Type 1 Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05378672 | Phase 3 | Completed |
Competing Products
20 competing products in Hypoglycemia